- Published on
Toxicology – Trimethobenzamide
Description
Trimethobenzamide, marketed as Tigan, is an antiemetic medication.
Forms and Uses
Trimethobenzamide is used for the treatment of nausea and vomiting.
The usual adult dosage is approximately:
250 mg orally three times daily
or
200 mg intramuscularly or rectally every 6–8 hours.
Toxic Dose
The toxic dose is not well established.
Significant toxicity generally requires ingestion of a large amount of trimethobenzamide.
Pathophysiology
Trimethobenzamide is a nonphenothiazine antiemetic that acts primarily by depressing the chemoreceptor trigger zone.
In overdose, toxicity is mainly related to anticholinergic effects.
Some patients may also demonstrate effects consistent with α-adrenergic blockade, including abnormalities in pupillary size.
Epidemiology
Trimethobenzamide poisoning is uncommon.
When overdose occurs, toxicity is usually mild.
Causes
Significant poisoning is often associated with intentional overdose.
In very young children, inappropriate exposure may raise concern for neglect or abuse.
In older children and adolescents, intentional self-poisoning should be considered when clinically appropriate.
Pregnancy and Lactation
The historical FDA classification listed trimethobenzamide as Pregnancy Category C.
Animal studies demonstrated possible teratogenic or embryotoxic effects, while adequate controlled human studies were unavailable.
Differential Diagnosis
Other causes of an anticholinergic toxidrome include:
Atropine
Scopolamine
and
Antihistamines.
Clinical Features
Acute overdose predominantly produces anticholinergic manifestations, although CNS depression and cardiovascular abnormalities may also occur.
Vital Signs
Possible abnormalities include:
Tachycardia
Hyperthermia
Hypertension
or
Hypotension.
HEENT
Dry mouth and difficulty swallowing may occur.
Mydriasis is more typical, although miosis has also been reported.
Cardiovascular Effects
Hypotension may develop because of peripheral vasodilation.
In massive overdose, quinidine-like cardiac effects may produce:
Myocardial depression
and
Ventricular dysrhythmias.
Pulmonary Effects
Respiratory depression may occur, particularly when severe muscle weakness develops.
Gastrointestinal Effects
Vomiting may occur during overdose.
Hepatic Effects
Hepatitis has occasionally been reported.
Musculoskeletal Effects
Acute dystonic reactions may occur.
Very large overdoses may produce severe muscular weakness or paralysis.
Neurologic Effects
CNS depression is an important manifestation of overdose.
Patients may develop:
Somnolence → increasing CNS depression → coma
Other reported effects include:
Tremor
Hallucinations
and
Seizures.
Laboratory Evaluation
Asymptomatic patients may not require laboratory testing.
In symptomatic patients, investigations may be used to assess both toxicity and alternative causes of altered mental status.
Recommended Laboratory Tests
Useful studies may include:
Serum electrolytes
BUN
Creatinine
Glucose
and other tests directed by the clinical presentation.
Respiratory Assessment
Pulse oximetry may be used in symptomatic patients.
Arterial blood-gas analysis may be considered when there is significant respiratory depression or impaired oxygenation.
ECG
An ECG is useful in significant poisoning to look for:
QRS widening or other cardiac conduction abnormalities.
Screening for Coingestants
In an intentional or uncertain overdose, acetaminophen and salicylate concentrations may be obtained to identify occult coingestion.
Treatment
Supportive care is the mainstay of treatment.
The amount ingested, timing of exposure, and possible coingestants should be determined whenever possible.
When to Seek Toxicology Assistance
Poison-center or toxicology consultation is appropriate when:
Severe or persistent symptoms develop
or when:
A coingestant, drug interaction, or underlying disease complicates the clinical picture.
Referral to a Health-Care Facility
Medical evaluation is appropriate when:
Toxic effects occur
Intentional poisoning is suspected
or
The exposure history is unreliable or complicated.
Admission
Hospital admission or prolonged observation is usually unnecessary after a minor exposure.
Admission may be appropriate when the patient develops:
Significant CNS depression
or
Cardiovascular toxicity.
Decontamination – Out of Hospital
Vomiting should not be induced.
Decontamination – In Hospital
The historical approach recommended gastric lavage after a recent large ingestion or when serious toxicity was present.
A single dose of activated charcoal was also recommended after a substantial recent ingestion.
Airway protection is important because severe overdose may cause CNS depression or seizures.
Antidote
There is no specific antidote for trimethobenzamide poisoning.
Treatment remains supportive and symptom-directed.
Seizure Treatment
Airway protection should be maintained.
Benzodiazepines are used for initial seizure control.
If seizures persist or recur, another anticonvulsant such as phenobarbital may be added.
Dystonic Reactions
Acute dystonic reactions may be treated with:
Diphenhydramine 25–50 mg IV, IM, or orally
with repeated treatment as needed.
The original recommendation suggests continuing oral antihistamine treatment for approximately 3–5 days to reduce the risk of recurrent dystonia.
Hypotension
When hypotension is associated with clinically important bradycardia, atropine may be used.
Volume support may include:
0.9% saline 10–20 mL/kg IV
with further fluid treatment adjusted according to the patient’s response and risk of fluid overload.
Vasopressor Support
If hypotension persists despite fluid therapy, a vasopressor may be required.
The historical regimen included dopamine, starting at approximately:
2–5 μg/kg/min IV
and titrating according to the hemodynamic response.
Other vasopressors may be added when required for persistent hypotension.
Patient Monitoring
Symptomatic patients should have:
Cardiac monitoring
Supplemental oxygen when needed
and
IV access.
Neurologic and respiratory status should also be monitored.
Expected Course and Prognosis
Anticholinergic manifestations usually reach their maximum severity within several hours.
In more significant poisoning, symptoms may require:
24 hours or longer
to resolve completely.
Most patients recover with supportive care.
Discharge From the Emergency Department
An asymptomatic patient with normal vital signs may be considered for discharge after:
Appropriate decontamination when indicated
Approximately 4–6 hours of observation
and
Psychiatric assessment when appropriate.
Discharge From Hospital
Hospitalized patients may be discharged when:
Toxic effects have resolved
and
The patient has returned to a level of functioning sufficient for self-care.
Psychiatric assessment should be completed when indicated.
Important Pitfalls
Trimethobenzamide overdose may resemble other anticholinergic poisonings, so alternative toxicologic causes should be considered.
Large overdoses may produce more than uncomplicated anticholinergic toxicity.
CNS depression, seizures, hypotension, QRS widening, and ventricular dysrhythmias may occur.
Dystonic reactions may recur after initial improvement.
The original recommendation therefore advises continuing treatment with diphenhydramine or another appropriate agent for several days after the acute reaction.
High-Yield Toxicology Pearls
Trimethobenzamide is a nonphenothiazine antiemetic that primarily produces anticholinergic toxicity in overdose.
The typical overdose syndrome includes:
Dry mouth + mydriasis + tachycardia + CNS depression
Other manifestations may include:
Hyperthermia
Hallucinations
Tremor
Seizures
Hypotension
and
Dystonic reactions.
Massive overdose may produce:
Myocardial depression + QRS widening + ventricular dysrhythmias
Respiratory depression may occur when severe weakness or CNS depression develops.
There is no specific antidote.
Treatment is mainly:
Airway support + monitoring + seizure control + treatment of dystonia + hemodynamic support
For seizures:
Benzodiazepines first-line
with phenobarbital considered if seizures persist.
For acute dystonic reactions:
Diphenhydramine is the principal treatment described.
For hypotension:
IV crystalloid → vasopressor support if needed
Most patients recover with supportive care, although significant anticholinergic effects may persist for 24 hours or longer.
The main clinical warning is:
Trimethobenzamide overdose is usually mild, but a large ingestion can progress beyond simple anticholinergic symptoms to coma, seizures, hypotension, and cardiac conduction abnormalities.